期刊
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
卷 31, 期 1, 页码 99-111出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2017.08.005
关键词
At risk; Risk stratification; RA prevention; Arthralgia; ACPA
类别
资金
- Arthritis Research UK [20525, 19652]
- Medical Research Council UK [G1001516]
- European Commission Innovative Medicines Initiative (BTCURE)
- European Commission Innovative Medicines Initiative (RTCURE)
- Bristol-Myers Squibb [IM101-328]
- MRC [G1001516] Funding Source: UKRI
- Medical Research Council [G1001516] Funding Source: researchfish
- Versus Arthritis [19652, 20525] Funding Source: researchfish
The field of rheumatology has made major contributions to medicine through the identification of cellular and molecular targets and the development of therapies for the treatment of an impressive range of immune-mediated inflammatory diseases such as rheumatoid arthritis. In recent years, new milestones have been achieved. These include the recognition of an at-risk state, characterized by disease specific autoantibodies in serum and inflammatory joint pain, and the initiation of studies seeking to prevent high-risk individuals from progressing to a state of clinically apparent arthritis. Here, the current state of the art of rheumatoid arthritis prevention is described, highlighting the importance of risk stratification and reporting on a growing portfolio of therapeutic interventions targeting different stages of the preclinical syndrome. Crown Copyright (C) 2017 Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据